New combo attack targets hard-to-treat KRAS G12C cancers

NCT ID NCT05358249

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called JDQ443, which targets a specific cancer-driving mutation (KRAS G12C), in combination with other drugs (trametinib, ribociclib, or cetuximab). The trial enrolls about 74 people with advanced solid tumors (like lung or colorectal cancer) that have this mutation and have already tried standard treatments. The goal is to find safe doses and see if these combinations can shrink tumors or control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JDQ443 (a KRAS G12C inhibitor) combined with trametinib, ribociclib, or cetuximab
What this could lead to: If successful, this could point toward new combination treatments that shrink or control advanced KRAS G12C cancers like lung and colorectal cancer.
What could go wrong: This is an early-phase trial (phase 1b/2) with only 74 participants, so results may not apply to all patients. Combinations may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm lung cancer non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG COLORECTAL CANCER COLORECTAL CARCINOMA COLORECTAL NEOPLASMS COLORECTAL TUMORS KRAS G12C MUTANT SOLID TUMORS NEOPLASMS, COLORECTAL NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CARCINOMA NONSMALL CELL LUNG CANCER

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
NYU School of Medicine

New York, New York, 10015, United States
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Bordeaux, 33076, France
Novartis Investigative Site

Lyon, 69373, France
Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site

Milan, MI, 20162, Italy
Novartis Investigative Site

Singapore, 168583, Singapore
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Madrid, 28050, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.